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“Take-home message” of the article: Different types of atrophy may be found in prostate 18 
with and without carcinoma. We showed that proliferative inflammatory atrophy (PIA) was 19 
significantly associated with carcinoma thus suggesting that PIA might play role in 20 
development of prostatic carcinoma. 21 
 22 
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ABSTRACT 1 
OBJECTIVE: The purpose of this study is to evaluate the extent and type of atrophy 2 
lesions, according to classification proposed by Working group in radical prostatectomy 3 
specimens obtained from patients with prostatic carcinoma and benign prostatic hyperplasia 4 
(BPH) and compare prevalence and types of atrophy between two investigated groups. 5 
METHODS: The total of 1096 slides from 50 patients with carcinoma and 277 slides from 6 
31 patients with BPH were histologically analyzed to evaluate the number of foci and type 7 
of atrophic lesions according to the new prostatic atrophy classification.  8 
RESULTS: Age, Gleason grade and TNM showed no significant correlation with the 9 
number of proliferative atrophy (PA) and proliferative inflammatory atrophy (PIA) foci 10 
(p>0.05). PIA was significantly more frequent in prostate with carcinoma (1.63 versus 1.27 11 
atrophic lesions per slide) (p<0.001) while PA displayed an increased frequency in BPH 12 
(2.28 versus 0.76 atrophic lesions per slide) (p<0.001).  13 
CONCLUSION: We confirmed that PA and PIA are common findings in prostate with and 14 
without carcinoma, but the question whether the inflammation produces tissue damage and 15 
proliferative atrophy or some other insult induces the tissue damage and atrophy directly, 16 
with inflammation occurring secondarily, is still unresolved.  17 
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1. INTRODUCTION 1 
Approximately 20% to 30% of the world’s cancer burden can be traced to infectious 2 
agents thought to act through the production of chronic infections and subsequent chronic 3 
inflammation [1-3]. In the prostate factors that determine the risk of developing clinical 4 
carcinoma are not well known; however it was clearly showed that chronic inflammation is 5 
associated with both postatrophic hyperplasia and focal simple atrophy [4,5]. The term 6 
proliferative inflammatory atrophy (PIA) was proposed to designate discrete foci of 7 
proliferative glandular epithelium with the morphologic appearance of simple atrophy or 8 
postatrophic hyperplasia occurring in association with inflammation. De Marzo et al. and 9 
Putzi and De Marzo suggested that PIA could be a precursor to prostatic adenocarcinoma 10 
directly, or may lead to carcinoma indirectly via development into high grade prostatic 11 
intraepithelial neoplasia (HGPIN) [5-9]. This finding supports a model whereby the 12 
proliferative epithelium in PIA may progress to HGPIN and subsequently to prostatic 13 
adenocarcinoma [8]. Investigations of frequency, distribution, proliferative state, molecular 14 
changes, and chromosome 8 gain in PIA also suggested connection between PIA, HGPIN 15 
and prostatic carcinoma [10-14]. This hypothesis is questioned by other authors, and its role 16 
as a precursor lesion has been controversial [15-21].  17 
Recently, Working group for histological classification of prostate atrophy lesions 18 
proposed classification of focal prostate epithelial atrophy lesions in the two main groups. 19 
The major distinction between proposed groups was content of inflammatory cells. Focal 20 
atrophy lesions that contain an increase in inflammation above that found in normal tissue 21 
were classified as PIA and those without inflammation were considered as a proliferative 22 
atrophy (PA). Each group, whether it is considered PIA or PA was sub-classified into the 23 
following types: simple atrophy, simple atrophy with cyst formation, post-atrophic 24 
  
3 
hyperplasia, partial atrophy and mixed lesions. Working group also noted that vast majority 1 
of focal atrophy lesions contained at least some inflammation that was beyond that found in 2 
normal epithelium and, therefore, most atrophy lesions were considered PIA [22].  3 
The purpose of this study is to evaluate the extent and type of atrophy lesions 4 
according to classification proposed by Working group, in radical prostatectomy specimens 5 
obtained from patients with prostatic carcinoma and benign prostatic hyperplasia (BPH) 6 
and compare prevalence and types of atrophy between two investigated groups. 7 
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2. MATERIAL AND METHODS  1 
Our study group included randomly chosen radical prostatectomy specimens of 50 2 
patients with prostatic adenocarcinoma diagnosed at the Department of Pathology, Leopold 3 
Franzens University Hospital Innsbruck, and simple open prostatectomy specimens of 31 4 
patients with benign prostatic hyperplasia (BPH) diagnosed at the Ljudevit Jurak 5 
Department of Pathology, Sestre milosrdnice University Hospital Zagreb. At the time of 6 
diagnosis all patients were clinically without lymph node or distant metastases and patients 7 
were not previously treated for prostatic cancer or other primary tumour. 8 
Lymphadenectomy was performed in 13 patients. 9 
The age range of the patients with carcinoma was between 43 and 79 years (median 10 
age 60.4), and age range of the patients with BPH was between 56 and 86 years (median 11 
age 69.7).  12 
Specimens were fixed in 10% buffered formalin, embedded in paraffin, cut at 5 µm 13 
thickness, and routinely stained with hematoxylin and eosin. The diagnosis of 14 
adenocarcinoma and BPH was histologically confirmed in all cases. We evaluated each 15 
case as a whole, without regard to separate parts. Cases with carcinoma consisted from 16 16 
to 42 slides, and cases with BPH consisted from 6 to 22 slides. All 1096 slides with 17 
carcinoma and 277 slides with BPH were microscopically sistematically analyzed to 18 
evaluate number of foci and type of atrophic lesions according the new atrophy 19 
classification proposed by Working group for histological classification of prostate atrophy 20 
lesions in two main types [22]. Following five subtypes are recognized. Simple atrophy is 21 
characterized by acini with relatively normal caliber that lack papillary fronds and were 22 
lined with atrophic cells. Simple atrophy with cyst formation is similar to simple atrophy 23 
but with some rounded and cyst-like glands. Post-atrophic hyperplasia is characterized with 24 
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smaller and round acini which appear in lobular distribution and often surrounding a 1 
somewhat dilated duct. In partial atrophy luminal cells contain less cytoplasm than normal, 2 
which is mostly clear. The architectural arrangement of glands can be similar to that of 3 
either simple atrophy or post-atrophic hyperplasia. Mixed atrophy contains admixed two or 4 
more above mentioned types [22].  Only atrophic lesions that contain an increase in 5 
inflammation above that found in adjacent tissue with normal appearing glands were 6 
classified as proliferative inflammatory atrophy. Atrophic lesions without inflammation or 7 
with inflammation which was sparse compared to adjacent tissue with normal appearing 8 
glands were considered as proliferative atrophy. Whole slides were screened under low 9 
magnification and type and quantity of inflammation were determined under high power 10 
field (400X). In cases of confluent areas of atrophy, foci were counted as separated only 11 
when intervening normal appearing glands or fibromuscular stroma without glands clearly 12 
made distinction between them. 13 
The differences in the appearance, extent and type of atrophy lesions between 14 
carcinoma and BPH were tested using Spearman rank order correlation test, Mann-Whitney 15 
U test, Wilcoxon matched pairs test and χ2 test. For all analyses type error of 5% was 16 
considered statistically significant (p<0.05). 17 
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3. RESULTS 1 
Patients with benign prostatic hyperplasia (BPH) were significantly older compared 2 
to patients with prostatic adenocarcinoma (p<0.05). Statistical analysis revealed no 3 
significant correlation between age and appearance of proliferative atrophy (PA) and 4 
proliferative inflammatory atrophy (PIA) in cases with carcinoma and BPH (p>0.05).  5 
The Gleason score and pTNM distribution are shown in Table 1 and 2. Eighteen 6 
tumors (36.0%) were moderately differentiated (Gleason score 5 and 6) and 32 (64.0%) 7 
were poorly differentiated (Gleason score 7 to 9). The most common Gleason grade was 3. 8 
In 45 (90.0%) tumors, one or both grades were three. Thirty-four tumors (68.0%) were 9 
confined to prostate and 16 (32.0%) were spread through prostatic capsule. Gleason grade 10 
and TNM showed no significant correlation with number of PA and PIA foci (p>0.05). 11 
In all 81 prostates (50 with carcinoma and 31 with BPH) foci with PA and PIA were 12 
found. Proliferative atrophy in BPH was significantly more frequent compared to PIA (2.28 13 
versus 1.27 focuses per slide) (p<0.001), whereas in cases with carcinoma PIA significantly 14 
outnumbered PA (1.63 versus 0.76 focuses per slide) (p<0.001) (Table 3).  15 
The most common type of PA in slides with carcinoma and BPH was type 2 or 16 
simple atrophy with cyst formation, and 0.45 and 1.67 focus per slide of this atrophy type 17 
was found, respectively (Fig. 1A). Out of total number of PA in BPH and carcinoma, 461 18 
(72.9%) and 489 (58.9%) were PA type 2 (Table 3).  19 
Statistical analysis revealed that cases with BPH showed significantly higher 20 
frequency of PA than cases with carcinoma (2.28 versus 0.76 atrophic lesions per slide) 21 
(p<0.001). 22 
On the contrary, PIA was significantly more frequent in prostate with carcinoma 23 
(1.63 versus 1.27 atrophic lesions per slide) (p<0.05). Increased PIA in prostate cancer in 24 
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comparison to BPH is mostly driven by type 1 (p<0.001) and type 5 (p<0.001) atrophic 1 
lesions (Table 3). 2 
The most common type of PIA in both analyzed groups was type 1 (simple atrophy) 3 
(Fig. 1B). In slides with carcinoma 616 (34.4%) or 0.56 foci per slides of type 1 atrophy 4 
were found. The second most frequent type was mixed lesions (type 5) with 394 (22.0%) or 5 
0.36 foci per slide. In BPH proliferative inflammatory atrophy type 1 was noted in 90 6 
(25.5%) or 0.33 foci per slide. Slightly less common types of PIA in BPH were type 2 and 7 
3 (0.31 and 0.32 foci per slide, respectively) (Table 3). 8 
PA and PIA were most commonly observed in peripheral zone of prostate. 9 
Inflammatory infiltrate around atrophic glands in cases of PIA mainly consisted of 10 
lymphocytes with varying numbers of macrophages.  11 
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4. DISCUSSION 1 
Chronic inflammation has been implicated in the development of tumors in wide 2 
range of organs including liver, stomach, pancreas and, urinary bladder [1-3]. Recent 3 
investigations also suggested connection between inflammation and prostatic carcinoma. 4 
Focal atrophy, which is often associated with chronic, and less frequently, acute 5 
inflammation has been especially suspicious [5-10]. De Marzo et al. proposed the term 6 
proliferative inflammatory atrophy (PIA) for this type of atrophy, and suggested its 7 
implication in prostatic carcinogenesis [5]. Unlike the type of prostatic atrophy associated 8 
with androgen depletion (hormonal atrophy), epithelial cells in PIA have low frequency of 9 
apoptosis, high proliferative index and share some molecular and genetics markers with 10 
prostatic carcinoma [11-14].  11 
However, this hypothesis is not confirmed by some others, mostly morphological 12 
and epidemiological investigations, which found no connection between PIA and prostatic 13 
carcinoma [15-21].  14 
In an autopsy study on 100 serially sectioned peripheral zone of the prostates from 15 
men older than 40 years, Billis found atrophic lesions in 85 of the 100 examined prostates, 16 
but did not confirm significant connection between the prevalence of atrophy and high 17 
grade prostatic intraepithelial neoplasia (HGPIN) or prostatic carcinoma [15].  18 
Billis and Magna also denied the role of atrophy in prostatic carcinogenesis and 19 
suggested possible role of ischemia in etiopathogenesis of prostatic atrophy [16]. Same 20 
authors investigated inflammatory atrophy in an autopsy study and observed inflammatory 21 
atrophy in 66% and atrophy without inflammation in 22% of analyzed cases. The authors 22 
found no association between the presence of inflammatory atrophy and the likelihood of 23 
cancer and no topographic association between atrophy and prostate cancer foci and 24 
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concluded that possible cause of inflammatory infiltrate associated with prostatic atrophy 1 
might be due to extravasated prostatic secretion, which was commonly noted in areas of 2 
eroded epithelium [17]. 3 
Bakshi et al. studied 79 consecutive prostate biopsies: 54% of initial biopsies were 4 
benign, 42% of the cases showed cancer, and 4% HGPIN or atypia. Postatrophic 5 
hyperplasia (PAH) was seen in 17% of benign initial biopsies with available follow-up. Of 6 
these, 75% had associated inflammation. There was no significant difference in the 7 
subsequent diagnosis of prostate cancer for groups with postatrophic hyperplasia, partial 8 
atrophy, atrophy, or no specific abnormality. The authors concluded that the subcategories 9 
of atrophy do not appear to be associated with a significant increase in the risk of diagnosis 10 
of prostate cancer subsequently [18].  11 
Similar findings were reported by Postma et al. in their investigation about 12 
connection of appearance and extent of atrophy in sextant needle biopsy and subsequent 13 
risk for development of prostatic carcinoma [19]. They observed atrophy lesions in 94% of 14 
analyzed cases but patients with extensive atrophy were not exposed to increased risk for 15 
development of HGPIN or carcinoma [19]. 16 
In our investigation, atrophy was found in all analyzed prostatectomy specimens 17 
with and without carcinoma. De Marzo et al. found that 55 foci of atrophy in specimens 18 
consisted of portion of tissue dissected immediately after radical prostatectomy from 42 19 
patients [5]. Similar frequency of atrophy is reported in two investigations of Billis (85% 20 
and 88%) and Postma (94%), who analyzed peripheral zone of prostate from autopsied men 21 
and sextant core needle biopsy from patients without diagnosed carcinoma [15,17,19].  22 
Our patients with benign prostatic hyperplasia (BPH) were significantly older than 23 
patients with carcinoma, but age was not found as relevant factor, which could influence 24 
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the appearance of proliferative atrophy (PA) and PIA in cases with BPH and carcinoma. On 1 
the contrary, Billis and Di Silverio et al. reported increased number of atrophic foci in aged 2 
patients [15,20]. We also found that Gleason score and TNM were not correlated with the 3 
number of PA and PIA foci in cases with carcinoma.  4 
 The most common type of PA was type 2, and the most common type of PIA was 5 
simple atrophy (type 1) in both analyzed groups. In investigation of De Marzo et al. the 6 
most frequently observed atrophy types were simple atrophy and simple atrophy with cyst 7 
formation [5]. Postma et al. also recently reported that simple atrophy is very common 8 
lesion in a sextant needle core biopsy from population without carcinoma [19]. 9 
We found that postatrophic hyperplasia (type 3), which is histologically most 10 
commonly confused with prostatic carcinoma, was almost equally distributed in cases with 11 
and without carcinoma. Approximately one focus of this atrophy type was usually found in 12 
every third slide in both analyzed cases.  13 
Anton et al. analyzed the presence, location and the number of foci of postatrophic 14 
hyperplasia. They found postatrophic hyperplasia in 32% of radical prostatectomy 15 
specimens and in 12% of cystoprostatectomy specimens and concluded that postatrophic 16 
hyperplasia is relatively common lesion but without any association with prostatic 17 
carcinoma [21]. 18 
 In our study, PA was more frequent in benign cases compared to PIA and these 19 
patients had also significantly higher number of PA foci compared to patients with 20 
carcinoma. On the other hand, in patients with carcinoma PIA was more prevalent 21 
compared to PA and slides from these patients contained significantly higher number of 22 
PIA focuses compared to slides with BPH. However, slides with carcinoma contained 23 
peripheral and transitional zone while slides with BPH were mainly composed of 24 
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transitional zone. Thus obtained different prevalence of atrophy in malignant and benign 1 
cases could partially reflect the difference in distribution between various anatomic 2 
compartments of the prostate. 3 
To our knowledge only two studies compared the appearance and frequency of 4 
inflammatory and non-inflammatory atrophy in patients with and without carcinoma. In 5 
these studies, no significant differences were found between the presence and types of 6 
atrophy in patients containing carcinoma with controls without carcinoma [15,17]. 7 
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5. CONCLUSION 1 
In conclusion, we confirmed that proliferative atrophy (PA) and proliferative 2 
inflammatory atrophy (PIA) are common findings in prostate with and without carcinoma, 3 
especially in the peripheral zone of prostate. Age, Gleason grade and TNM showed no 4 
significant connection with number of PA and PIA foci. PIA outnumbered PA in cases with 5 
carcinoma compared to benign prostatic hyperplasia (BPH), but the question whether the 6 
inflammation produce tissue damage and proliferative atrophy or some other insult induces 7 
the tissue damage and atrophy directly, with inflammation occurring secondarily, is still 8 
unresolved.  9 
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Table 1. Distribution of Gleason grades and scores in 50 patients with prostatic 1 
adenocarcinoma. 2 
                                3 
Gleason grades with scores Number of cases % 
5 (2+3) 3 6.0 
5 (3+2) 4 8.0 
6 (3+3) 11 22.0 
7 (3+4) 20 40.0 
7 (4+3) 3 6.0 
8 (3+5) 3 6.0 
8 (4+4) 3 6.0 
8 (5+3) 1 2.0 
9 (4+5) 2 4.0 
Total 50 100 
 4 
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Table 2. Distribution of pTNM in 50 patients with prostatic adenocarcinoma. 1 
 2 
                         3 
pTNM Number of cases % 
T2aNxMxR0 1 2.0 
T2aNxMxR1 1 2.0 
T2aN0MxR1 1 2.0 
T2bNxMxR1 1 2.0 
T2bN0MxR0 5 10.0 
T2cNxMxR0 19 38.0 
T2cNxMxR1 6 12.0 
T3aNxMxR0 3 6.0 
T3aNxMxR1 5 10.0 
T3aN0MxR0 3 6.0 
T3aN0MxR1 1 2.0 
T3bNxMxR1 1 2.0 
T3bN0MxR1 3 6.0 
Total 50 100 
                      4 
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Table 3. The number and type of atrophy lesions in 1096 slides of 50 patients with prostatic 1 
adenocarcinoma and in 277 slides of 31 patients with benign prostatic hyperplasia 2 
 3 
 Prostatic adenocarcinoma (n=1096) Benign prostatic hyperplasia (n=277) 
 PA* PIA** PA* PIA** 
 
Number 
(%) 
Number 
per slide 
Number 
(%) 
Number 
per slide 
Number 
(%) 
Number 
per slide 
Number 
(%) 
Number 
per slide 
Type 
1 
117 
(14.1%) 
0.11 
616 
(34.4%) 
0.56 
70 
(11.1%) 
0.25 
90 
(25.5%) 
0.33 
§Type 
2 
489 
(58.9%) 
0.45 
339 
(18.9%) 
0.31 
461 
(72.9%) 
1.67 
86 
(24.4%) 
0.31 
Type 
3 
37 
(4.5%) 
0.03 
332 
(18.5%) 
0.30 
6 
(0.9%) 
0.02 
88 
(24.9%) 
0.32 
§Type 
4 
58 
(7.0%) 
0.05 
110 
(6.2%) 
0.10 
22 
(3.5%) 
0.08 
24 
(6.8%) 
0.09 
Type 
5 
129 
(15.5%) 
0.12 
394 
(22.0%) 
0.36 
73 
(11.6%) 
0.26 
65 
(18.4%) 
0.22 
Total 
830 
(100%) 
0.76 
1791 
(100%) 
1.63 
632 
(100%) 
2.28 353 1.27 
 4 
*PA – proliferative atrophy; **PIA – proliferative inflammatory atrophy 5 
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§type 2 and §type 4 atrophy are not yet formally considered proliferative inflammatory 1 
atrophy or proliferative atrophy since studies of these lesion looking at proliferation have 2 
not been published [22] 3 
 4 
Legend: 5 
Type 1 – simple atrophy 6 
Type 2 – simple atrophy with cyst formation 7 
Type 3 – post-atrophic hyperplasia 8 
Type 4 – partial atrophy 9 
Type 5 – mixed lesions 10 
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    1 
A           B 2 
Figure 1. The most common type of proliferative atrophy in slides with benign prostatic 3 
hyperplasia and prostatic adenocarcinoma was simple atrophy with cyst formation (A), 4 
while simple atrophy was most frequent type of proliferative inflammatory atrophy in both 5 
analyzed groups (B). (Both microphotographs made under magnification of 200x.) 6 
